These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10913806)

  • 1. Power calculation for clinical trials when the outcome is a composite ranking of survival and a nonfatal outcome.
    McMahon RP; Harrell FE
    Control Clin Trials; 2000 Aug; 21(4):305-12. PubMed ID: 10913806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.
    Matsouaka RA; Betensky RA
    Stat Med; 2015 Feb; 34(3):406-31. PubMed ID: 25393385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining stratified and unstratified log-rank tests in paired survival data.
    Oakes D; Feng C
    Stat Med; 2010 Jul; 29(16):1735-45. PubMed ID: 20572124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination based on rank tests in clinical trials.
    Wang H; Chen B; Chow SC
    J Biopharm Stat; 2003 Nov; 13(4):735-51. PubMed ID: 14584719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint.
    Porcher R; Lévy V; Chevret S
    Control Clin Trials; 2002 Dec; 23(6):650-61. PubMed ID: 12505243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for the weighted rank statistics with paired survival data.
    Jung SH
    Stat Med; 2008 Jul; 27(17):3350-65. PubMed ID: 18205148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 9. Study duration for group sequential clinical trials with censored survival data adjusting for stratification.
    Kim K
    Stat Med; 1992 Aug; 11(11):1477-88. PubMed ID: 1329172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.
    Koziol JA; Feng AC
    Stroke; 2006 Oct; 37(10):2644-7. PubMed ID: 16946150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size estimation for non-inferiority trials of time-to-event data.
    Crisp A; Curtis P
    Pharm Stat; 2008; 7(4):236-44. PubMed ID: 17583558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
    Lièvre M; Marre M; Chatellier G; Plouin P; Réglier J; Richardson L; Bugnard F; Vasmant D
    Control Clin Trials; 2000 Aug; 21(4):383-96. PubMed ID: 10913814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating a treatment effect with the accelerated hazards models.
    Chen YQ; Wang M
    Control Clin Trials; 2000 Aug; 21(4):369-80. PubMed ID: 10913811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for changing the test statistic during a clinical trial.
    Lawrence J
    J Biopharm Stat; 2002 May; 12(2):193-205. PubMed ID: 12413240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate nonparametric analysis for the two-period crossover design with application in clinical trials.
    Johnson WD; Grender JM
    J Biopharm Stat; 1993 Mar; 3(1):1-12. PubMed ID: 8485530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 20. A hierarchical rank test for crossover trials with censored data.
    Brittain E; Follmann D
    Stat Med; 2011 Dec; 30(30):3507-19. PubMed ID: 22139739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.